J2E cells produce rapid, fatal erythroleukemias in vivo but still respond to erythropoietin (epo) in vitro by dierentiating, proliferating and remaining viable in the absence of serum. Mutant epo receptors were introduced into these cells to determine whether they could in¯uence the dierent biological responses to epo in vitro and the development of erythroleukemias. Three mutant receptors were used as cytoplasmic truncation mutants D257 and D321 (above box 1 and below box 2 respectively), and the cytoplasmic point mutant W282R (defective for JAK2 activation). Strikingly, the D321 mutation produced a hyper-sensitive response in vitro to epoinduced dierentiation and viability, but not to proliferation. In contrast with the D321 receptor, the D257 and W282R mutants inhibited all biological responses to epo due to impaired JAK2 phosphorylation. Signi®cantly, erythroleukemias took almost twice as long to develop with cells containing the W282R mutation, indicating that JAK2 plays an important role in the emergence of these leukemias. These data demonstrate that mutant epo receptors dominantly altered responses of J2E cells to epo in culture and the development of erythroleukemias. Oncogene (2000) 19, 953 ± 960.
Introduction
Erythroleukemias represent the highly malignant M6 subtype of acute myeloid leukemias (Bennett et al., 1976) . Mutations to the erythropoietin (epo) receptor have been implicated in the genesis of erythroleukemias as alterations to the receptor gene have been found in erythroleukemic cell lines (Chretien et al., 1994 Winkelmann et al., 1995) . In addition, constitutive activation of the epo receptor, by either an R129C substitution in the extracellular domain or via interaction with Friend virus glycoprotein gp55, cause erythroleukemias in mice (Li et al., 1990; Longmore and Lodish, 1991; Ruscetti et al., 1990; Yoshimura et al., 1990b) . Although it has been reported only one of ten human erythroleukemias examined bore an epo receptor mutation (Le Couedic et al., 1996) , autocrine production of the hormone has been implicated in the development of some red cell leukemias (Mitjavila et al., 1991) . Thus, epo and its cognate receptor can be considered as proto-oncogenes.
Epo normally maintains viability, enhances proliferation and stimulates terminal dierentiation of erythroid precursors (Jelkmann, 1992; Koury and Bondurant, 1992; Krantz, 1991) . Upon hormone binding the epo receptor dimerizes, Janus kinase 2 (JAK2) is activated and tyrosine residues in the cytoplasmic domain of the receptor phosphorylated (Matthews et al., 1996; Watowich et al., 1992; Witthuhn et al., 1993) . These phosphorylated tyrosines act as docking sites for signaling proteins including Signal Transducer and Activator of Transcription 5 (STAT 5), the p85 subunit of phosphatidylinositol 3-kinase (PI3-kinase) and phosphatases SHP-1 and SHP-2 (Damen et al., 1995a,b; Gobert et al., 1996; Klingmuller et al., 1995 Klingmuller et al., , 1996 Klingmuller et al., , 1997 Penta and Sawyer, 1995; Quelle et al., 1996; Sharlow et al., 1997; Tauchi et al., 1995 Tauchi et al., , 1996 Yi et al., 1995) . Although Shc and Grb2 bind to the epo receptor and stimulate the Ras/Raf/MAP-kinase pathway (Barber et al., 1997; Bittorf et al., 1994; Carroll et al., 1991; Cutler et al., 1993; Gobert et al., 1995; He et al., 1995; Miura et al., 1994b; Tilbrook et al., 1996a; Torti et al., 1992) , their precise binding locations on the receptor have not been identi®ed.
The J2E erythroleukemic cell line was generated by transformation of erythroid precursors with the raf and myc oncogenes (Klinken et al., 1988) . Despite being immortalized at the proerythroblast/basophilic erythroblast stage of erythroid development, J2E cells still respond to epo in vitro by dierentiating biochemically with hemoglobin production, and morphologically by undergoing cellular alterations which result in a proportion of cells enucleating to form reticulocytes (Bus®eld et al., 1993a,b; Bus®eld and Klinken, 1992; Klinken et al., 1988) . In addition, exposure to epo promotes cell division and maintains viability in the absence of serum (Chappell et al., 1997; Tilbrook et al., 1996a) . Despite being transformed, epo signaling in J2E cells appears perfectly normal ± these cells express the characteristic 1000 epo receptors on the surface of erythroid cells (Klinken et al., 1988) and the receptor, JAK2, STAT5, ras-GAP, PI-3 kinase and MAP-kinase all show typical phosphorylation kinetics after hormonal stimulation (Tilbrook et al., 1996a,b) . These cells produce a rapid, fatal erythroleukemia when introduced into mice, but the pathogenesis can be ameliorated by ex vivo epo treatment (Farr et al., 1995) . In contrast with J2E cells, the mutant J2E-NR subclone remains alive, does not mature or divide in response to epo (Klinken and Nicola, 1990; Tilbrook et al., 1996a) , due to a lack of the tyrosine kinase lyn . Additionally, the J2E-NR cells contain 300 ± 500 surface epo receptors (Klinken and Nicola, 1990) .
In this study we took a dierent approach to understanding epo receptor function in erythroleukemic cells. Mutated epo receptors were introduced into J2E and J2E-NR cells to determine whether the exogenous receptors could interfere with epo-dependent dierentiation, proliferation or viability in vitro, and in¯uence the development of erythroleukemias in vivo. Three mutant forms of the receptor were introduced into the cells: (i) D257, which is truncated above box 1 and contains only ten amino acids in the cytoplasmic region (Watowich et al., 1994) ; (ii) D321, which is truncated below box 2 and has all potential tyrosine phosphorylation sites removed; and (iii) W282R, which has an amino acid substitution preventing JAK2 activation and mitogenic signaling (Miura et al., , 1994a . Data presented here show that the mutated receptors dominantly aected epo-induced signaling and the emergence of erythroleukemias.
Results

Overexpression of exogenous epo receptors in J2E cells
To determine the eect of exogenous epo receptors on in vitro dierentiation, proliferation and viability, as well as erythroleukemias in vivo, four receptor constructs were introduced into J2E cells, viz. mutants D257, D321 and W282R, together with wild type controls. Clones infected with a wild type receptor, tagged with hemaglutinin (HA) at the carboxy terminus to distinguish it from the endogenous receptor, were termed J-wt-HA, while those with the D257, D321 and W282R receptors were termed J-D257, J-D321 and J-W282R (Figure 1 ). Figure 2a shows the RNA content of exogenous and endogenous epo receptors in parental and infected J2E cells. The levels of viral epo receptor RNA were generally three to ®ve times that of the normal gene (Figure 2b ). Despite the excessive amounts of viral RNA, expression of the endogenous gene did not decline. Almost identical data were obtained with the J2E-NR transfectants N-wt-HA and N-D321 (data not shown). This suggests that a negative feedback loop is not operating to suppress endogenous epo receptor mRNA production.
Mutant epo receptors alter surface receptor numbers modestly
Surface receptor numbers were determined for cells containing the various epo receptor constructs. As we have described previously (Klinken et al., 1988) , roughly 1000 epo receptors were present on the surface of parental J2E cells (Figure 3) . No increase in surface receptors was detected in J-wt-HA cells (Figure 3 ) despite a signi®cant increase in mRNA (Figure 2) . Similarly, the 500 surface receptors on J2E-NR cells were unaected by introduction of the wild type receptor construct (Figure 3) . Although the receptor level of J2E-NR cells was below the 1000 receptors per cell seen with J2E cells, increasing wild type receptor RNA did not raise surface receptor numbers. These data indicate a tightly regulated control mechanism for restricting wild type surface receptor numbers, which is independent of mRNA levels. However, surface epo receptor numbers approximately doubled with the introduction of mutant receptors D257, D321 and W282R in J2E cells, and increased threefold with the D321 mutant in J2E-NR cells. These results suggest that abnormal receptors may aect regulatory mechanisms for controlling surface receptor numbers. It is possible that protein folding and/or translocation may be important ways of controlling surface receptor levels (Hilton et al., 1995 (Hilton et al., , 1996 . Figure 1 Epo receptor constructs. A wild type (wt) epo receptor with a C-terminal HA tag (wt-HA) was generated. The D257 mutant is truncated above box 1, while the D321 is truncated below box 1 and 2 but lacks any cytoplasmic tyrosine residues. W282R has an arginine substituted for tryptophan at residue 282 
Box 1 and box 2 mutant receptors suppress epo-induced differentiation
The eects of introducing foreign epo receptors on the in vitro dierentiation of J2E cells was determined by benzidine staining for hemoglobin production ( Figure  4a ). No dierences in epo-induced dierentiation were observed between the parental J2E cells and those expressing the HA-tagged receptor. However, severe inhibition of hemoglobin production was noted with cells containing the D257 truncation, and the W282R mutation. In contrast, the D321 truncation had little impact on the production of hemoglobin in response to epo. When globin protein content in these cells was analysed (Figure 4b ), similar eects were noted i.e. epo promoted globin production in J2E, J-wt-HA and J-D321 cells, whereas J-D257 and J-W282R cells had reduced levels of globin in the absence of epo, and failed to respond to hormonal stimulation. While it is not clear why the J-D257 and J-W282R cells have reduced levels of globin protein without epo stimulation, J2E cells do not produce epo in an autocrine manner (Klinken et al., 1988) . These data indicate that in J2E erythroleukemic cells, the D257 and W282R receptors dominantly suppress dierentiation signals, whereas the D321 mutant does not act as a dominant inhibitor.
Dominant effect of mutated epo receptors
Having observed the eect of two mutant receptors on the dierentiation of these erythroleukemic cells at maximal concentrations of epo, a dose response to epo was conducted to determine whether the cells responded to dierent concentrations of hormone. No dierences were observed between J2E and J-wt-HA cells (Figure 5a ± c) . Strikingly, the J-D321 cells synthesized hemoglobin at much lower concentrations of epo than J2E cells (Figure 5a ). In fact, half maximal stimulation was achieved at 0.01 U/ml epo, compared with 0.1 U/ml for J2E cells. When the eect on cell survival was examined, the J-D321 cells also responded to much lower concentrations of epo ( Figure 5b ). However, the D321 mutation did not render J2E cells hypersensitive to epo-induced proliferation ( Figure 5c ). As anticipated from the data presented in Figure 4 , the J-D257 and J-W282R cells did not dierentiate in response to any concentrations of epo up to 10 U/ml, a saturating concentration of ligand ( Figure 5a ). Moreover, epo-initiated viability and proliferation were inhibited in these cells (Figure 5b ,c). Since J2E-NR cells do not proliferate or dierentiate, but remain alive, in response to epo (Klinken and Nicola, 1990; Tilbrook et al., 1996a) , a dose response curve was generated to test the eects of the D321 receptor on the viability of J2E-NR cells. Figure 5d shows that epo-induced viability of cells with D321 receptor was enhanced compared with J2E-NR cells. The truncated receptor, therefore, was able to in¯uence the J2E-NR sub-line in its only known biological response to epo.
Thus, each of the mutant receptors had a dominant eect on J2E or J2E-NR cells in vitro ± they either suppressed epo-induced dierentiation, cell survival and proliferation, or they generated hypersensitivity with respect to hemoglobin production and viability. Clearly mutations or deletions in the box 1 and box 2 regions were deleterious to dierentiation and viability, whereas loss of the carboxy terminal region below box 2 promoted hypersensitivity to some responses to epo.
Epo receptor and JAK2 phosphorylation
In an attempt to determine the biochemical reasons for the eects of the mutated receptors on epo-induced n=3). The Kd for the various transfectants ranged between 280 and 420 pM which is characteristic of J2E cells (Klinken and Nicola, 1990; Klinken et al., 1988; Tilbrook et al., 1996b) Enhanced tyrosine phosphorylation of proteins in J-D321 cells was detected at lower concentrations of epo than the parental J2E cells, but no increased phosphorylation of proteins with epo was observed in either J-W282R or J-D257 cells (data not shown). Phosphorylation of the epo receptor and JAK2 were then examined, particularly in J-D321 and J-W282R cells. Figure 6a and b shows the characteristic phosphorylation of these molecules in J2E cells. Although JAK2 was activated normally in J-D321 cells, epo receptor phosphorylation was reduced to approximately 20% of that seen in the parental cells (Figure 6a,b) . Since the D321 epo receptor lacks cytoplasmic tyrosine residues and migrates at *40 kDa on SDS ± PAGE, the phosphorylation detected here is due to endogenous receptors in these cells. Importantly, no phosphorylation of the receptor of JAK2 was detected in J-W282R cells, con®rming the block in JAK2 activation imposed by this mutation.
Development of erythroleukemias is influenced by mutant epo receptors
Having observed that altered epo receptors can aect the biological responses to epo in vitro, we examined the development of erythroleukemias in vivo. Figure 7 shows the characteristic mortality induced by J2E cells that we have reported previously (Farr et al., 1995; Lai et al., 1995) . No dierence in latent period was observed with J-D321 cells, and the cumulative mortality curve was essentially superimposable with J2E cells (Figure 7) . Moreover, animals injected with J-D321 cells developed identical symptoms to those treated with J2E cells, i.e. hepatosplenomegaly and severe anemia. In contrast, leukemias developed much slower in mice that had received J-W282R cells ( Figure  7) , and hind limb paralysis was observed in several moribund mice. These observations were identical for each of three clones analysed. To con®rm that the cells introduced into mice were responsible for the erythroleukemias, spleens were removed for DNA extraction and the epo receptor mutations determined by sequence analysis (data not shown). From these results it was concluded that the W282R mutation inhibited erythroleukemia development, suggesting that epo receptor-mediated activation of JAK2 was important in the genesis of these leukemias.
Discussion
Data presented in this study demonstrate that mutations in the epo receptor alter responses to epo in vitro and in vivo. J2E cells express endogenous epo receptors and upon epo stimulation proliferate and dierentiate into red blood cells (Bus®eld and Klinken, 1992; Klinken et al., 1988) . Strikingly, ectopic expression of the W282R mutant prevented the J2E cells from dierentiating, proliferating or remaining viable after epo stimulation. In marked contrast, cells containing the D321 truncated receptor were hyper-responsive to epo in vitro i.e. they synthesized hemoglobin and maintained viability at much lower concentrations of epo. However, the J-D321 cells were not hyperresponsive with respect to proliferation, in contrast with previous reports which showed that removal of the carboxy terminal 90 amino acids resulted in hypersensitivity to epo-stimulated proliferation in non-erythroid cells (D'Andrea et al., 1991) . The intracellular environment of the J2E erythroleukemic cells may favor epo signaling towards erthyroid terminal dierentiation, rather than proliferation. This study also demonstrates for the ®rst time the inhibitory eects of the D257 truncation on the dierentiation of erythroleukemic cells. Severe membrane-proximal truncations have been shown previously to prevent signaling for proliferation and viability in heterologous cell systems (D'Andrea et al., 1991; Watowich et al., 1994; Zhuang et al., 1995) , but not dierentiation. The hypersensitive response in vitro of J2E cells bearing the D321 truncation is reminiscent of the benign erythrocytosis and polycythemia observed in patients with naturally occurring truncations of the receptor (Arcasoy et al., 1997; de la Chapelle et al., 1993; Furukawa et al., 1997; Kralovics et al., 1997; Sokol et al., 1995) . Like the erythroid progenitors in patients with abbreviated receptors, the J-D321 cells dierentiated at much lower concentrations of epo. Extended activation of JAK2, STAT5 and p42 MAP kinase has been observed in J-D321 cells (Sarna et al. in preparation), which is similar to changes induced by a naturally occurring truncation of the epo receptor (Arcasoy et al., 1999) . Furthermore, Klingmuller et al. (1995) showed epo receptors defective in SHP-1 binding had prolonged JAK2 phosphorylation, and Sharlow et al. (1997) demonstrated mutation of the SHP-1 binding site enhanced hemoglobin production by SKT6 erythroleukemic cells. Thus, SHP-1 may be less able to dephosphorylate JAK2 in J-D321 cells due to the lack of phosphotyrosine docking sites on the D321 receptor, resulting in extended JAK2 activation.
Structural and biochemical analyses have demonstrated that epo induces receptor dimerization (Barber et al., 1994; Livnah et al., 1996; Matthews et al., 1996; Watowich et al., 1992 Watowich et al., , 1994 . The dominant action of mutant receptors in J2E cells suggests that they heterodimerize with wild type receptors upon ligand binding, thereby altering normal receptor function. This is supported by evidence in 32D cells transfected with mutant and wild type receptors, which showed that mutant receptors dominantly inhibited signaling from the wild type receptor (Barber et al., 1994; de la Chapelle et al., 1993) . It is likely that the dominant eects of the mutant receptors in 32D cells are due to heterodimers with wild type receptors since the mutants are inactive on their own (Watowich et al., 1994) . Nakamura and Nakauchi (1994) proposed that the dominant negative eect of a truncated receptor over the wild type receptor was most probably due to receptor heterodimerization. Signi®cantly, Chretien et al. (1996) found that coexpression of wild type and truncated epo receptors in¯uenced epo-induced dierentiation of TF-1 cells. These results highlight the importance of xepo receptor dimerization in accurate transmission of intracellular signals and biological outcomes.
Finally, the exogenous W282R receptor had a signi®cant impact on the emergence of erythroleukemias in vivo. Mice injected with cells containing this construct took almost twice as long to develop leukemias as those treated with parental J2E cells, or those bearing the D321 truncation. Our interpretation of these data is that epo is required, at least in part, for the development of these erythroleukemias and the inability of the W282R receptor to signal via JAK2 suppresses leukemia establishment or progression. Recently, translocations involving JAK2 have been implicated in the genesis of certain leukemias (Lacro- Peeters et al., 1997) , and speci®c inhibition of JAK2 activity shown to prevent acute lymphoblastic leukemia cell growth in vivo (Meydan et al., 1996) . The results presented here support a key role for JAK2 in leukemogenesis. Interestingly, the D321 truncation had no impact on erythroleukemia development, suggesting the hypersensitivity to epo in vitro did not translate to altered kinetics in vivo. It has been reported that serum epo concentrations are elevated in patients with M6 erythroleukemias (Johannsen, 1989) , and it is possible, therefore, that the heightened sensitivity of J-D321 cells in vitro may be masked by raised levels of epo in erythroleukemic mice. This study emphasizes the signi®cance of intracellular signaling from activated receptors in the development of erythroleukemias.
Materials and methods
Cell culture
J2E (Klinken et al., 1988) and J2E-NR (Klinken and Nicola, 1990 ) cell lines were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum (GIBCO, Australia) at 378C in a humidi®ed atmosphere of 5% CO 2 . Cells were induced to dierentiate with 5 U/ml recombinant human epo (Eprex, Janssen-Cilag, Australia). Cell viability was determined by 0.4% eosin exclusion, while hemoglobin production was detected by benzidine staining (Cooper et al., 1974) . DNA synthesis was measured by [ 3 H]-thymidine incorporation in RPMI 1640 medium (Bus®eld and Klinken, 1992) .
Transfection of epo receptors
Mutant epo receptors D257 (Watowich et al., 1994) , D321 (Watowich et al., 1999) and W282R , together with wild type epo receptor tagged at the carboxy terminus with HA (wt-HA), were subcloned into the retroviral vector MSCV 2.2 (Hawley et al., 1994) . Plasmids were transfected into PA317 amphotropic packaging cells and virus-containing supernatants added to J2E or J2E-NR cultures before selection in Geneticin (Sigma, St. Louis, MO, USA) as described previously .
DNA and RNA analysis
Integration of retroviral constructs in clones isolated from methylcellulose cultures was determined by PCR ampli®ca-tion using primers to exon II and IV of the epo receptor genomic sequence (Kuramochi et al., 1990) : 5'-TA-CAGCTTCTCATACGAGC-3' (exon II) and 5'-AGCGT-CAAGATGAGAGGGT-3' (exon VI). This generated a 534 bp fragment for the viral epo receptor constructs which could easily be distinguished from the endogenous gene. Speci®c viral integration sites in the host cell genome, were identi®ed by Southern blots probed with a 32 P-labeled epo receptor cDNA (D'Andrea et al., 1989) .
RNA was prepared by the method of Gough (1988) and 20 mg of total RNA separated through agarose gels as described previously (Tillbrook et al., 1996b) . Following transfer the membranes were hybridized to 32 P-labeled probes for epo receptor or glyceraldehyde 3-phosphate dehydrogenese (GAPDH), washed and scanned by PhorphorImager (445SI, Molecular Dynamics, Sunnyvale, CA, USA). Quantitation was performed using ImageQuant v1.0 software (Molecular Dynamics, Sunnyvale, CA, USA).
Protein analyses
Lysates (1 ± 3 mg) were immunoprecipitated with antibodies to epo-receptor (Yoshimura et al., 1990a) , JAK2, phosphotyrosine (06-255; 05-321; Upstate Biotechnology, Lake Placid, NY, USA) or HA (MMS-101P; BAbCO Richmond, CA, USA). For immunoblots 100 mg protein was separated by SDS ± PAGE and transferred to nitrocellulose membranes as we described in detail elsewhere (Tilbrook et al., 1996b) . Membranes were incubated with antibodies to epo-receptor (Yoshimura et al., 1990a) , globin (#55447; Cappel Research, Organon Technika, Belgium), JAK2, phosphotyrosine (06-255; 05-321; Upstate Biotechnology, Lake Placid, NY, USA) and visualized by enhanced chemiluminescence (Amersham, Bucks, UK). The presence of truncated epo receptor proteins was detected by immunoblotting, while expression of wt-HA was con®rmed by immunoprecipitation and immunoblotting.
Cell surface receptor analyses
Surface receptor numbers were determined by binding of [ 125 I]-epo to cells at 378C for 70 min in the presence of NaN 3 to inhibit internalization for Scatchard analyses as we have detailed previously (Klinken and Nicola, 1990; Klinken et al., 1988; Tilbrook et al., 1996b) . These experiments were performed three times.
Erythroleukemias
Mice were inoculated with 10 6 cells intravenously as described previously (Farr et al., 1995) , and sacri®ced as they became moribund. Hematocrits were taken and in®ltration of leukemic cells into various organs determined. The presence of the leukemic cells containing the normal (J2E) or mutated epo receptors (J-W282R and J-D321) was determined by PCR analysis and DNA sequencing of spleens isolated from ®ve mice in each group.
